Description of Research Expertise:
Application of high through-put technology to gain insights into the biology of human cancers, with special interest in GU cancers.
Selected Publications:
Priti Lal, Kosj Yamoah, Amy Ziober, Amy Walker, Wenting Zhou, Elaine Spangler, Charnita Zeigler-Johnson, Michael Feldman, Timothy R. Rebbeck.: Racial Differences in the Distribution of Prostate Tumor Biomarkers and Treatment Failure: The SCORE Study Clinical Cancer Research : 2015.
Kosj Yamoah, Michael Hiroshi Johnson, Voleak Choeurng, Kasra Yousefi, Zaid Haddad, Robert Benjamin Den, Priti Lal, Michael D Feldman, Adam Dicker, Eric A. Klein, Elai Davicioni, Timothy R. Rebbeck, Edward M. Schaeffer: A novel biomarker signature which may predict aggressive disease in African-American men with prostate cancer. Journal of Clinical oncology : 2015.
Kosj Yamoah, M.D., Ph.D.; Amy Walker, M.S.; Elaine Spangler, M.S.; Charnita M Zeigler-Johnson, M.D., Ph.D.; Bruce Malkowicz, M.D.; David I Lee, M.D.; Adam P Dicker, M.D., Ph.D.; Priti Lal, M.D.: African-American race is a predictor of seminal vesicle invasion following radical prostatectomy. Clinical Genitorurinary Cancer : 2014.
Priti Lal, MD: Chapter 39: Prostate.
Diagnostic molecular pathology. Diagnostic Molecular pathology, 2nd edition : 2015.
David J. Vaughn, MD,Wei-Ting Hwang, PhD,Priti Lal, MD,Mark Rosen, MD Maryann Gallagher, Peter J. O’Dwyer, MD: Phase II Trial of the CDK 4/6 Inhibitor Palbociclib in Patients with Retinoblastoma Protein Expressing Germ Cell Tumors Cancer : 2014.
Stephen Michael Keefe, Daniel Heitjan, Meliessa Hennessey, Janelle Robinson, Kristine Mykulowicz, Amy Marshall, Orvar Gunnarsson, Ronac Mamtani, David J. Vaughn, Jean H. Hoffman-Censits, Katherine L. Nathanson, Priti Lal, Daniel A. Pryma, Scott Eliasof, Edward Graeme Garmey, Roger B. Cohen, Naomi B. Haas;: Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC). ASCO : 2014.
Mathew LK, Lee SS, Skuli N, Rao S, Keith B, Nathanson KL, Lal P, Simon MC: Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2a Activity. Cancer Discov 4 (1): 53-60,2014.
Priti Lal, MD: Applications of OCT 4 in Diagnostic immunohistochemistry Leong's Manual of Diagnostic Antibodies for Immunohistology 3rd edition : 2014.
Priti Lal, MD: Application of GATA 3 in diagnostic immunohistochemistry Leong's Manual of Diagnostic Antibodies for Immunohistology 3rd edition : 2014.
Priti Lal, MD: Application of SALL4 in diagnostic immunohistochemistry Leong's Manual of Diagnostic Antibodies for Immunohistology 3rd edition : 2014.